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Abstract: This paper offers a comparison of the 
drug strategies and plans adopted over the last 
five years by six intergovernmental organisations 
engaging 148 countries in four continents. It 
informs decision-makers, professionals and 
researchers working in the area of international 
drug policy about the way in which countries of 
the same region have decided to strategically 
approach drug-related security, social and health 
problems. Drug strategies and plans offer 
interesting insights both when analysed 
individually and when compared across regions. 
This paper describes the way in which drug 
strategies are structured and addresses their 
priorities and objectives. It looks at the main 
approaches to demand and supply reduction and 
analyses the manner in which these interventions 
are referred from region to region. The content 
analysis reveals interesting similarities but also 
important differences. When seen in the light of 
the current international drugs policy debate, 
regional drug strategies may provide an 
important contribution for assessing the drug 
problem at international level.
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Although neither the political declarations nor the action plans 
explicitly require the creation of regional drug strategies, they 
may have provided the impetus for neighbouring countries to 
agree on a common regional approach. Indeed, the decade 
between 1998 and 2009 witnessed the appearance of 
intergovernmental (regional) drug plans and strategies 
involving a number of African and Asian countries, and the 
renewal of action plans and strategies in the Americas and 
Europe (Figure 1).
I  Introduction to the paper
International drug control has been consolidated over the last 
50 years with the adoption, by United Nations (UN) member 
states, of three UN drug conventions (1) and two political 
declarations and their corresponding plans of action (2). In 
particular, the two plans of action, endorsed in 1998 and 
2009, marked a change towards a more systematic and 
structured drug policy approach and called on UN member 
states to adopt comprehensive and balanced national drug 
strategies and establish regional mechanisms.
(1)  The United Nations Single Convention on Narcotic Drugs 1961; the 1971 
United Nations Convention on Psychotropic Substances; and the United 
Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988.
(2)  General Assembly Twentieth Special Session, Political Declaration and Plan 
of Action, UNGASS 1998; and High-level segment Commission on Narcotic 
Drugs, Political Declaration and Plan of Action on International Cooperation 
towards an Integrated and Balanced Strategy to Counter the World Drug 
Problem, Vienna, 2009.
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FIGURE 1
Timeline of regional drug strategies and action plans
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This paper offers a brief comparison of the drug strategies and 
plans adopted in the last five years by six regional 
intergovernmental organisations (hereafter regional drug 
strategies) (3), covering 148 countries in four continents 
(Table 1).
TABLE 1
Current regional drug strategies and plans in regional 
organisations
Region Organisation
Current 
number of 
Member 
States
Title(s) of the document(s)
Africa African Union 
(AU)
54 AU plan of action on drug 
control 2013–17
Economic 
Community 
of West 
African States 
(ECOWAS)
15 Political declaration on the 
prevention of drug abuse, 
illicit drug trafficking and 
organised crime in West 
Africa (Abuja Declaration, 
2008)
Regional action plan to 
address the growing 
problem of illicit drug 
trafficking, organised crime 
and drug abuse 2008–11 (1)
America Organization 
of American 
States (OAS)
35 Hemispheric drug strategy 
2011–15
Plan of action 2011–15
Asia Association 
of Southeast 
Asian Nations 
(ASEAN)
10 ASEAN work plan on 
combating illicit drug 
production, trafficking and 
use 2009–15
Shanghai 
Cooperation 
Organisation 
(SCO)
6 Counter narcotic strategy of 
the Shanghai Cooperation 
Organisation Member States 
2011–16
Europe European 
Union (EU)
28 EU drugs strategy 2013–20
EU action plan on drugs 
2013–16
(1)  Extended for two years by the ECOWAS heads of States and Governments in 
2012.
These strategies offer interesting insights both when analysed 
individually and when compared across regions. This paper 
describes the way in which drug strategies are structured and 
addresses their priorities and objectives. It looks at the main 
approaches to demand and supply reduction and analyses the 
way in which, for instance, prevention and treatment are 
targeted and whether harm reduction interventions are 
mentioned to the same extent across regions. It also looks at 
the way in which drug control measures are identified and 
discusses if and how the geographical and social context 
might have influenced the choice of actions. In this paper, the 
ground for comparison is given by the existence of an official 
document in the field of drugs, such as a political declaration, 
a strategy and/or a plan of action, that has been adopted at 
minister or head of state level and which envisages a time 
(3)  By convention, in this paper, the term ‘regional drug strategies’ refers to 
strategies on drugs and drugs action plans unless stated otherwise. 
frame for achievements. It does not analyse other relevant 
regional initiatives in the field of drugs, such as cooperation 
projects involving many regional and international actors. This 
paper does not review bilateral agreements in the field of 
drugs, which are common in all the regions and countries 
considered, nor does it explore other strategic documents, 
such as regional security or health plans, which, although they 
may include a drugs component, are not drugs specific.
The main aim of this work is to inform decision-makers, 
professionals and researchers working in the area of 
international drug policy about the way in which countries of 
the same region have decided to strategically approach 
drug-related security, social and health problems. It can 
ultimately serve to juxtapose a variety of policy options 
designed to face similar challenges and can enrich current 
drug policy debate.
The paper is divided into two parts: Part I is a comparative 
analysis, which highlights the differences and similarities 
between the structure and the content of selected 
documents; and Part II profiles each intergovernmental 
organisation, describing briefly its institutional structure, 
strategy and action plan and the regional coordination 
mechanism.
Regional drug strategies and plans of action establish 
visions, set far-reaching objectives and describe future 
actions. The policy approaches and concrete objectives 
outlined in these documents are varied, and an analysis 
of them reveals not only how regions position themselves 
in many aspects of the drugs policy agenda but also 
where the regions stand in relation to each other. It is not 
the aim of this paper to compare interventions on the 
ground. Rather, as these political, strategic documents 
express the official will of a group of countries to tackle 
the security and social problems caused by the drugs 
phenomenon, the paper will focus on the high-level 
commitments, priorities and proposed actions that, 
whether or not they are feasible, realistic or effective, are 
intended to influence current drug policy at world level.
Regional drug strategies — between 
high-level policy commitments and 
actions on the ground
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I  Part Ia — The structure of drugs strategies and action plans
The nine documents analysed in this paper (Table 1, p. 3) are 
of different types: three are described as drugs strategies, five 
as action plans and one as a political declaration.
The three drugs strategies (EU, OAS and SCO) and the 
political declaration of ECOWAS have a relatively similar 
structure: a preamble stating the main principles and goals is 
followed by an outline of the key priority areas. The five action 
plans (EU, ECOWAS, OAS, ASEAN, AU), designed to be more 
specific, identify more concrete objectives and actions. Some 
of them also present, in table format, specific elements such 
as timetables, indicators or responsible actors.
Although, as is to be expected, the structure of the documents 
is not uniform, they all follow the same approach: identification 
of main policy goals and descriptions of the objectives and 
actions needed to achieve them.
The EU, OAS and ECOWAS publish two documents: a timed 
strategy (or policy) document to identify the policy objectives 
and an action plan that breaks down objectives into actions 
and targets. The OAS and EU even distinguish two different 
policy processes: first, the adoption of a strategy and, six 
months later (in case of the EU), its action plan. Both the AU 
and ASEAN directly adopted plans of action, where policy 
objectives and concrete actions are presented together. The 
AU plan even includes an implementation matrix that singles 
out outcomes and outputs, performance indicators, means of 
verifications and risks.
I Main principles and objectives in drug strategies
Principles as the basis of drug strategies
The general principles stated in the introduction of the drug 
strategies and plans are the foundation of the regional 
policies, describing the areas where objectives and actions 
are based and where much attention is focused. A call for 
respect for human rights in the implementation of drug policy 
is prominent in the EU, OAS and AU strategies. The EU’s drug 
This part describes the main features, objectives and 
approaches presented in the drugs strategies and plans 
adopted by the six intergovernmental (regional) organisations.
It looks at the structure of the documents and their principles, 
pillars, objectives and targets. It highlights important elements 
of drug policy such as evaluation, monitoring, quality of 
interventions and best practice and analyses the way in which 
they are addressed in the texts.
It also looks at the content of the strategies, comparing 
objectives in the areas of supply reduction and drug control, 
and discusses if and how the geographical and social context 
influences the choice of actions. It addresses the area of 
demand reduction, comparing the variety of approaches to 
prevention, treatment and harm reduction. It looks at the issue 
of prisons and alternatives to punishment, and at the role of 
civil society in supporting drug policy design and 
implementation. Finally, it addresses the area of  
international cooperation as presented in the strategies.
Regional drug policies are shaped by, and to some extent 
reflect, the differing drug situations and historical, social and 
political situation. The strategies and plans analysed in this 
paper reflect and are influenced by this sociogeographical 
variety.
There is no agreed definition of the elements that should 
make up a drugs strategy or action plan. However, 
according to a study by the EMCDDA in 2002, a drugs 
strategy should describe the set of instruments or 
mechanisms aimed at directing drug policy principles 
towards objectives. The aim of a drug action plan, in 
contrast, is to implement and deliver the principles of the 
strategy, detailing objectives, targets, resources and 
responsibilities and laying out a time frame for achieving 
objectives and meeting targets (1).
(1)  EMCDDA/European Commission, 2002. Strategies and coordination 
in the field of drugs in the European Union, www.emcdda.europa.eu. 
See under Topics (A–Z) > Policy and law > National strategies > 
Coordination in the field of drugs.
Strategies and action plans
Part I
Comparative analysis
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only by more effective use of law enforcement against the 
trafficking and production of drugs. The SCO’s strategy reveals 
the organisation’s firm belief that drug trafficking and related 
crime undermines security in the region.
Main objectives
A reduction in the drugs phenomenon is the objective of all 
strategies and plans analysed. There are, however, slight 
differences in the way this objective is presented and pursued, 
revealed by nuances in the language used in the different 
documents.
For instance, according to its strategy document, the EU 
intends to contribute to a measurable reduction of both 
demand and supply of drugs. Moreover, it adds, for the first 
time, another aim: a reduction in the social and health risks 
and harms caused by drugs. The EU aims, by 2020, to have 
contributed to an overall impact on key aspects of the EU 
drugs situation. The Hemispheric strategy and plan of the OAS 
is in many ways similar to the EU strategy, in that it envisages 
that signatory countries will adopt a comprehensive, balanced 
and multidisciplinary approach to the drugs phenomenon. The 
main goal of the AU plan is improvement in the health, security 
and socioeconomic well-being of African people, while the 
ECOWAS focuses on reinforcement of the region’s capacity to 
fight drug trafficking, drug abuse and crime.
The two Asian plans specify as their main objective a 
substantial reduction in the drugs phenomenon in the ASEAN 
and SCO regions. In 1998, ASEAN set a goal of establishing a 
drug-free region by 2015. In 2007, this goal was redefined as a 
‘significant reduction in production, abuse and trafficking of 
illicit drugs’. The SCO has a similar aim, namely a ‘drastic 
reduction’ in the drugs phenomenon by 2017.
I Pillars of drug strategies
Drug strategies and action plans are usually divided into a few 
main areas or so-called pillars. Some, such as supply 
reduction and demand reduction, are found in almost all 
action plans although supply reduction is slightly more 
common, being presented as main pillar or a key area — 
together with crime prevention and control measures — in 10 
cases whereas demand reduction is a key area in eight.
Other areas that are particularly emphasised in some plans 
include capacity building, which is identified as a key area in 
the African strategies and in the OAS documents; 
international cooperation, which has its own chapter in the EU, 
SCO and OAS plans; and monitoring, research and evaluation, 
which is a specific pillar of the African and European plans. 
Coordination is a key area or pillar only of the EU action plan.
strategy explicitly mentions the European Charter of 
Fundamental Rights while that of the OAS refers to the 
Universal Declaration of Human Rights. The strategies and 
plans of the ECOWAS, ASEAN and SCO place particular 
emphasis on individuals’ right to safety and security and the 
threat to this attributable to drug use and trafficking.
Another important principle explicitly mentioned in most of the 
documents is common and shared responsibility for drug policy. 
Reaffirmed and consecrated by the United Nations General 
Assembly Special Session (UNGASS) in 1998, the principle 
aims to reconcile the dualism that for many decades has placed 
producing and consuming countries in conflict. This principle, 
defined by the International Narcotics Control Board (INCB) in 
2012 as a cooperative partnership based on a common 
understanding of a shared problem and a coordinated action 
towards a common goal, is strong in the OAS strategy, and is 
mentioned in both the African documents (AU and ECOWAS) 
and in the EU strategy, which bases its external relations in the 
field of drugs on this principle. The ASEAN strategy envisages 
that member countries will adopt collective and shared 
responsibility for realisation of the vision of a drug-free region (4). 
The OAS strategy emphasises the individual responsibility of 
each country, highlighting the principles of integrity, national 
sovereignty and non-intervention in the internal affairs of states.
The need to reduce poverty and foster development is central 
to both African strategies, along with crime prevention and 
drug control. The ECOWAS sees the promotion of economic 
and social development as a parallel measure to combating 
drug trafficking and related crime while the AU’s drugs plan 
makes express reference to the Millennium Development 
Goals (5). Both view crime as a barrier to the region’s social 
and economic development.
The key principle that underlies both the Asian strategies is 
that peace, security and stability in the region will be achieved 
(4)  ASEAN Ministerial Meeting on drugs Matters, 1–4 September 2013.
(5)  The Millennium Development Goals (MDGs) are eight international 
development goals that all United Nations member states have agreed to 
achieve by the year 2015. The goals are: eradicating extreme poverty and 
hunger; achieving universal primary education; promoting gender equality and 
empowering women; reducing child mortality rates; improving maternal health; 
combating HIV/AIDS, malaria, and other diseases; ensuring environmental 
sustainability; and developing a global partnership for development.
n  Respect for human rights
n  Common and shared responsibility
n  Integrity, national sovereignty and non-intervention in 
the internal affairs of states
n  Reduce poverty and foster development
n  Effective law enforcement
Principles of drug strategies
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progressed from the establishment of a regional monitoring 
centre (action plan 1990) to the need to better understand all 
aspects of the drugs phenomenon and the impact of 
responses to it (drug strategy 2013–20).
Although it was the first, Europe is not the only region to have 
this objective. The African strategies also recognise the need 
for monitoring systems. A key priority of the new drugs plan of 
the AU is to strengthen the capacity to establish monitoring 
systems able to collect data, analyse trends and link them to 
evidence-based responses and effective policies. National and 
regional observatories have already been established in South 
Africa, Kenya and Senegal. The ECOWAS plan also 
acknowledges that reliable data to assess the phenomenon 
are lacking and envisages that USD 1.5 million will be needed 
to strengthen reliable data collection and monitoring. This 
implicitly seems to respond to the concerns of the INCB 
(2012), which has described the lack of capacity for the 
collection and analysis of drug-related data in Africa as a 
serious challenge.
Setting of national and regional observatories is also a priority 
in the Americas. In the OAS, the drug monitoring role is 
performed by the Inter-American Observatory on Drugs (OID), 
the statistical, information and scientific research body of the 
Inter-American Drug Abuse Control Commission (CICAD). The 
OAS’s strategy invites member states to establish or 
strengthen national observatories on drugs, develop national 
information systems and foster scientific research.
The areas chosen as the main pillars, whether demand, 
coordination or capacity building, are those that each region 
considers particularly important. However, the fact that a 
specific subject does not feature as a key area or main pillar 
does not necessarily mean that that topic will receive no 
attention. For instance, the OAS does not describe research 
and monitoring as a specific pillar but this area is addressed 
throughout the action plan (Table 3).
I Monitoring, implementation and evaluation
Drugs monitoring
All the analysed drugs strategies and plans recognise the 
importance of generating reliable information as a basis for 
decision-making. The newer strategies generally aim to create 
systems and processes that will help to better understand all 
aspects of the drugs phenomenon and to measure and 
evaluate the impact of policy interventions.
The EU was the first intergovernmental organisation to identify 
this need, in its first action plan, in 1990. This led to the 
creation of a European network of reliable and scientifically 
driven monitoring centres headed by an EU agency, the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (6). Since then, each EU strategy or plan has 
included a chapter on monitoring. This development has 
(6) CELAC (1990) European Plan to Combat Drugs.
TABLE 3
Pillars and key areas in drug plans
Number of 
pillars or key 
policy areas
Supply 
reduction, 
crime 
prevention, 
control 
measures, 
money 
laundering
Demand 
reduction, 
prevention, 
treatment, 
rehabilitation, 
reintegration 
HIV/AIDS 
prevention
International 
cooperation
Enhancing 
monitoring 
(research and 
evaluation) 
Capacity 
building; 
political 
leadership; 
institutional 
strengthening
Coordination
OAS Plan of Action 2011–15 5 ü ü (1) ü ü ü
ECOWAS action plan 
2008–11 (2)
5 ü ü (1) ü ü ü
AU plan of action on drug 
control 2013–18
4 ü ü ü ü
ASEAN work plan on 
combating illicit drug 
production trafficking and 
use 2009–15
3 ü ü (1) ü
SCO counter narcotic 
strategy 2011–16
4 ü ü ü (2) ü
EU drugs action plan 
2013–16
 5 ü ü ü ü ü
(1)  The document distinguishes two distinct pillars or includes separate chapters that focus on the same category: ‘supply reduction, crime prevention and/or drug 
control’. 
(2)  The document distinguishes two distinct pillars or includes separate chapters that focus on the same category: ‘prevention and treatment’.
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mid-term review in 2012 and a final assessment in 2015. The 
EU is the only region that anticipates an external evaluation of 
its strategy at the end of its term in 2020, in addition to 
biennial progress reviews carried out by the European 
Commission.
Quality, evidence base and best practice in drug 
strategies
Although the emphasis varies, most of the documents identify 
quality, best practice and standards as the main criteria and 
keywords linked to the concept of effectiveness in drug-related 
interventions. In addition, in several strategies scientific 
evidence is presented as the guiding principle on which — 
increasingly — drug policy decisions should be based.
This approach is exemplified by the EU drugs strategy, which 
is based on an evidence-based approach to the drugs 
phenomenon, and by the strategies and plans of the AU and of 
the OAS. The AU plan, in particular, recognises the need to 
implement evidence-based responses to address the health 
and social impact of drug use while the OAS strategy and plan 
call for the production of evidence in the drugs field and its 
wide implementation throughout the hemisphere. The 
ECOWAS strategy mentions evidence-based as the principle 
on which strategic papers must be developed to inform the 
heads of state and governments of the magnitude of the drug 
problem and the threat it presents to the security and 
development of the region.
(8) www.cicad.oas.org
The ASEAN plan addresses the issue of annual surveys of 
opium and cannabis cultivation and production, and also aims 
to establish baseline statistical data in member countries so 
that progress towards achieving the goals set out in the action 
plan goal can be measured.
Implementation and evaluation
The OAS strategy stands out in its promotion of evaluation and 
assessment in all areas of drugs. The document suggests 
integrating the scientific community into the design, 
implementation and evaluation of policies, and invites 
member countries to promote periodic and independent 
evaluations in the areas of demand and supply reduction, 
linking the results of evaluation to the allocation of resources.
The EU strategy has a similar vision, devoting an entire chapter 
to information, research, monitoring and evaluation. The 
strategy promotes evaluation of policies and interventions in 
the areas of demand and supply reduction and proposes that 
it is good practice that should be exported in international 
relations.
All the plans and strategies analysed address the need to 
assess progress in implementation, identifying a variety of 
mechanisms for doing so, including regular progress reviews 
(annual or biennial), high-level conferences, mid-term 
evaluations and final evaluations. However, the level of detail 
varies. Some plans identify actors, expected results and 
performance indicators and call for an overall evaluation of 
progress while others are less specific about the actors, 
schedule of implementation and assessment of expected 
outcomes.
The majority of strategies envisage that progress in 
implementing plans will be assessed by means of annual or 
biennial reports. In the OAS, CICAD is in charge of monitoring 
the implementation of the plan via the Multilateral Evaluation 
Mechanism (MEM), created in 1998 to evaluate drugs control 
policies and the countries’ progress. It will review the 
assessment of the plan in 2016. In addition, the ECOWAS 
Commission Operation Plan calls upon its Mechanism and 
Evaluation Mechanism (MEM) to provide guidance for 
implementation of actions, and will review its plan annually. In 
Africa, biennial reports on the status of the implementation of 
the AU Plan are submitted to the AU conference of ministers. 
The Counter narcotic strategy of the SCO refers to an 
implementation mechanism by which countries of the region 
will review the results of the strategy at the meetings of the 
competent bodies and annually at the meeting of the senior 
officials of the SCO. As for the ASEAN, ASOD (7) is charged 
with gathering baseline data and producing annual reviews, a 
(7) ASEAN Senior Officials on Drug Matters (ASOD).
At the Sixth Summit of the Americas in Colombia (2012), 
the heads of state and governments entrusted the OAS 
with the task of preparing a study on the drug problem in 
the Americas. This study consisted of a comprehensive 
analysis of policies applied in the Americas, highlighting 
the strengths, weaknesses and challenges in the 
implementation of those policies. The findings of the 
study served as the basis of an analytical report and a 
scenarios analysis examining new approaches for the 
OAS leaders to find a better way to address the drugs 
phenomenon. The analytical report and the four 
scenarios — Together, Pathways, Resilience and 
Disruption — of what could happen in the future and the 
results that could be expected in each scenario were 
released at the Seventh Summit in Antigua Guatemala in 
June 2013 (8).
OAS mandate to assess drug policies in the 
Americas
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Thus, it is clear that the expansion of best practice, standards 
and quality into the area of drug supply is a new, widely shared 
trend.
The need to establish science-driven quality standards to 
maximise effective interventions is also recognised in many 
documents. The EU looks at the adoption of quality standards 
in the areas of prevention, treatment, risk and harm reduction 
and rehabilitation. The AU aims to develop and implement 
minimum quality standards for drug use prevention and 
treatment and the OAS strategy invites its members to make 
sure that services for drug-dependent persons are evidence 
based and follow internationally accepted quality standards.
I Civil society
The need for the support of non-governmental organisations 
(NGOs) and civil society in the development and 
implementation of drug policies and programmes is identified 
in all strategies analysed.
The ASEAN plan attributes great importance to civil society 
organisations, calling on them to contribute to the 
implementation of the regional plan through civic awareness 
initiatives, research-based communication campaigns, health 
and social services, and prevention and education 
programmes, including in the workplace.
The OAS strategy also attributes to civil society a key role in 
the development and implementation of drug policies and 
programmes. Two areas are particularly emphasised: supply 
reduction, with civil society being invited to complement 
programmes with crime prevention initiatives; and alternative 
development, the assisting in the design and implementation 
of supply reduction projects. The demand reduction section of 
the OAS strategy also mentions engaging NGOs to contribute 
to the formulation of drug policy. The SCO strategy envisages 
that civil society will be used to promote prevention messages, 
the AU calls on its member states to develop partnerships 
with civil society and the ECOWAS plan calls on civil society to 
contribute to data collection and monitor trends, monitor and 
report corruption, and raise awareness on the dangers of drug 
trafficking and drug abuse.
A similar approach is envisaged in the EU strategy, which 
gives wide support to the participation of civil society in drugs 
policy, calling on the Civil Society Forum (9) and civil society 
organisations to provide a number of activities: providing 
information on the implementation of the drugs action plan, 
assisting in the development and implementation of drug 
(9)  The Civil Society Forum (CSF) serves as a platform for the informal exchange 
of views and information between the European Commission and civil society 
organisations. In 2013, 40 organisations joined the organisation for a two-year 
period and the first plenary meeting took place on 24–25 June 2013.
Best practice is another key term that crops up regularly in 
drugs policy documents. Originally reserved for the demand 
reduction area, it is now increasingly common for the concept 
of best practice to be applied in the field of supply reduction, 
as shown by some of the strategies analysed. The OAS 
strategy, for example, applies the concept to the areas of 
institutional capacity, demand reduction and supply reduction 
and control measures, declaring that it is essential to increase 
the availability and improve the analysis of data to aid policy 
decisions in the area of supply reduction. Similarly, the EU 
strategy calls for best practice to be developed and 
implemented in the areas of demand, supply and in its 
relations with third countries. In particular, the strategy calls 
on the EU to work towards more effective policies in supply 
reduction, through policy evaluation, better understanding of 
the drug markets and increased effectiveness of law 
enforcement responses. The AU plan invites Member States to 
develop and adopt codes of conduct for judges and 
prosecutors and develop basic minimum standards for 
effective community policing, police service delivery and 
cross-border cooperation, according to international 
standards and norms. The ASEAN drugs action plan promotes 
the sharing of experiences and the lessons learned across the 
countries of the region, in particular in the area of alternative 
development, to share best practice in reducing cultivation of 
illicit crops. One of the five key areas identified in the ECOWAS 
plan is the need to obtain reliable data to assess the 
magnitude of the drug trafficking and abuse problems through 
the sharing of best practice.
A comparison of previous and recently updated drug 
strategies (EU, OAS, AU) shows a trend towards the 
development of an ‘empirical’ approach to drug policy. It 
seems that the revision of a strategy provides the 
opportunity to establish new or more scientific 
arguments. This evolution is nowhere more evident than 
in the EU drug strategies and plans, which date back to 
1990. It is no accident that the last EU strategy — the 
ninth strategic policy document adopted by the EU — 
calls for a balanced, integrated but above all evidence-
based approach. The EU is the only intergovernmental 
organisation to make the concept of ‘evidence base’ a 
cornerstone of its regional policy on drugs. This overall 
trend, is however, equally visible in the new OAS and AU 
plans. Both, recently updated, show important ‘empirical’ 
innovations compared with previous versions. In all three 
cases — EU, OAS and AU — it can be argued that the 
role of scientifically driven institutions and of civil society 
has been a key factor driving an increasingly knowledge-
based and scientific approach to the field of drugs.
Are drug policies becoming more empirical?
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The OAS takes a similar stance, the first objective of its action 
plan being to improve comprehensive and balanced measures 
aimed at reducing the supply of drugs, through the use of 
intelligence based on the findings of monitoring and 
evaluation. An intelligence-led approach also forms the 
backbone of drug supply measures in the EU, while the AU 
plan stresses the need to more effectively increase 
coordination, collaboration and capacity-building towards 
more efficient law enforcement and harmonised actions to 
address drug trafficking and related organised crime. 
Increasing regional cooperation against drug trafficking is also 
one of the main objectives of the ECOWAS plan, which 
stresses the need to attract political attention and devote 
more resources to this growing phenomenon. Both African 
plans envisage the harmonisation of legislation in the area of 
drug trafficking.
Geopolitics in the variety of subjects covered
Perhaps more than in any other policy area considered in the 
analysed documents, the drug supply reduction measures 
envisaged reflect the geopolitical situation in the region and 
the different features of the specific drug markets.
This is probably why the strategy of the SCO, which includes 
Russia and China among its members, is the only one to 
mention Afghanistan and, indeed, dedicates an entire chapter 
to the threat from this country. Of the other strategies or plans, 
only that of the EU identifies Afghanistan as a country with 
which cooperation should be enhanced. Another subject 
prominent in some, but not all, strategies is prevention of arms 
proliferation. Stopping the diversion of firearms, ammunition, 
explosives and other related materials is an issue in the OAS 
strategy and a concern in the African plans. Corruption (drug 
related) is comprehensively addressed in both African 
strategies and is touched upon in the OAS and the SCO action 
plans, with a reference to the international instruments 
against corruption. There is no mention of corruption in the EU 
strategy.
Conceptually linked to corruption, but receiving attention in all 
strategies is drug-related money laundering. The ECOWAS 
action plan places a strong emphasis on reinforcing structures 
to detect and combat money laundering with special financial 
intelligence units in charge of collection, analysis and 
dissemination of information concerning potential money 
laundering including the financing of terrorism. ECOWAS also 
calls on the judiciary system to designate specialised courts 
and/or judges to handle money laundering and economic 
crimes. The ASEAN plan proposes the implementation of 
legislative and enforcement measures, such as asset 
forfeiture and anti-money laundering initiatives, as the first 
step in dismantling criminal organisations involved in 
trafficking of illicit drugs. The SCO envisages more active 
policies and holding a dialogue with the EU member states 
twice a year.
I  Part Ib — Content of regional drug strategies
I Supply reduction
Main aims in reducing the supply of drugs
All analysed documents have similar objectives in the area of 
supply reduction, such as strengthening law enforcement, 
increasing intelligence, exchange and improving border 
controls. The regions take a largely uniform approach, with law 
enforcement measures and methods to tackle drug trafficking 
and drug-related crime being generally very similar across 
continents. However, a small, but interesting, difference is 
noticeable in attitudes towards the final aim in the area of 
supply reduction, revealed by the terms used and the 
establishment of clear deadlines.
The ASEAN plan confirms its goal of achieving a drug-free 
region by 2015, a target set by the ASEAN foreign ministers in 
2000 and reaffirmed ever since. Experts in the region agreed 
the definition of ‘drug free’: an insignificant quantity of illicit 
crops will remain and manufacturing and trafficking of drugs 
will be an insignificant phenomenon. Similarly, a drug-free 
status is the main aim of the SCO’s plan, which calls for a 
drastic reduction in the scale of illicit trafficking of narcotics 
and precursors by 2017.
Both plans are aimed at implementing, albeit with a tighter 
deadline, the 2009 UN political declaration and plan of action, 
which establish 2019 as a target date for states to eliminate or 
reduce significantly and measurably the illicit cultivation, 
production and trafficking of — and demand for — illicit drugs.
The other regional strategies and plans analysed in this paper 
are not so precise in setting a date for achievement of their 
expressed objectives and targets, and describe their goal as a 
reduction in the phenomenon. For instance, the stated 
objective in the supply reduction chapter of the EU drugs 
strategy 2013–20 is to contribute to a measurable reduction 
in the availability of illicit drugs by using an intelligence-led 
approach to identify the criminal organisations causing the 
most harm or posing the most serious threat and make them a 
priority target. Although no target date for achievement is 
expressed, 2020 should be considered the end point when 
progress will be evaluated.
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better law enforcement training and capacity-building in 
general.
The OAS and ECOWAS action plans, for example, aim to use 
currently available information to develop policies in the field 
of drug supply, while the AU, EU and the OAS action plans aim 
to improve the collection of data and strengthen the evidence 
base underpinning supply reduction policies. Measuring the 
effectiveness of supply reduction interventions is a clear aim 
of the EU strategy and OAS plan. The EU aims to develop a set 
of key indicators in the field of drug supply within the 
EMCDDA, while the OAS plans to implement a hemispheric 
information system in the area of drug supply within CICAD.
The drugs plans of the two African organisations include a 
strong reminder of the need for political mobilisation against 
drug trafficking, corruption, terrorism and in favour of 
strengthening the structures aimed at tackling drug-related 
crime (training, equipment and capacity-building). The ASEAN 
strategy is defined by an emphasis on a drastic reduction in 
the scale of the drugs problem while the SCO focuses on the 
threat from Afghanistan. The call for a balanced approach to 
supply reduction is particularly strong in the OAS and EU 
strategies, but can also be seen in other documents (ASEAN, 
AU), which envisage increased sustainability of local 
populations and the environment as a cornerstone of anti-
drugs measures. 
Alternative development
Alternative development is addressed in all strategies, with a 
strong focus on providing alternative livelihoods, championing 
farmers’ rights, reducing poverty and increasing food security. 
The EU promotes financial and technical support for 
alternative development programmes that are realistic with 
respect to rural development and which respect human rights 
and food security. The OAS links alternative development with 
the promotion of social inclusion and poverty reduction 
programmes, calling for collaboration in this area of civil 
society. The issue of poverty and food insecurity in relation to 
cultivation of illicit crops is also addressed in the ASEAN 
strategy. In Africa, the ECOWAS political declaration 
recognises the need to provide cannabis farmers with 
legitimate, profitable and sustainable livelihoods. The AU 
drugs action plan, while tackling drug supply, aims to integrate 
drug control into poverty reduction strategies to develop 
political, social and economic integration of those people, 
often vulnerable and marginalised, who are involved in illicit 
cultivation of drugs.
In general, the supply reduction chapters of regional drugs 
strategies are notable for their attention to social aspects, 
human rights and the potential unintended and undesirable 
consequences of supply reduction interventions, in particular 
cooperation with the Financial Action Task Force (FATF), the 
Eurasian Group and other specialised organisations to combat 
money laundering and financing of terrorism.
Another broad subject treated similarly across regions is the 
proceeds of crime. The ECOWAS, AU and OAS strategies 
envisage national and regional collaboration or even the 
creation of mechanisms (AU and OAS) to exchange 
information and detect, retrieve and confiscate drug-related 
laundered funds and assets. The AU plan goes as far as 
proposing to change existing laws if necessary. Tackling the 
proceeds of crime is also addressed in the EU action plan. 
Judicial cooperation is to be strengthened, to target the 
confiscation of the proceeds of crime and money laundering.
Another key element in supply reduction activities present in 
almost all strategies is the diversion of precursors. The ASEAN 
plan calls for renewed efforts against precursors and for the 
development of partnerships with the chemical and 
pharmaceutical industries. The EU and OAS strategies also 
prioritise the problem of precursors diversion, planning and/or 
reinforcing community mechanisms for diversion control.
The subject of pharmaceuticals is also increasingly present in 
the supply reduction chapters of strategies, in particular the 
role of internet and online pharmacies. The most 
comprehensive approach to the abuse and diversion of 
pharmaceuticals is found in the OAS strategy. However, this 
phenomenon is also addressed in the EU action plan, which 
aims to tackle the use of certain pharmacologically active 
substances (10) as cutting agents for illicit drugs. The ASEAN 
drugs plan mentions the widespread use and impact of 
cybertechnology on trafficking in narcotic drugs and 
psychotropic substances, including the issue of online 
pharmacies.
Measurability and effectiveness in supply reduction
Another notable trend in recent strategies and plans is an 
increased emphasis on gaining a better understanding of the 
nature of the drug markets and measuring the effectiveness of 
supply reduction interventions. The need for drug supply data 
to better understand the dynamics of the illegal drugs market 
and thus better tackle organised crime is recognised. This 
perhaps reflects a general trend in law enforcement policies, 
with data increasingly being considered a useful tool for both 
operational purposes and strategic decision-making. The need 
for increased effectiveness, in terms of a greater reduction in 
the illicit supply of drugs, or in some case eliminating supply 
altogether, is expressed in all documents. It is generally 
thought that this will be achieved by increasing cooperation 
between national law enforcement agencies, together with 
(10) As defined in Directive 2011/62/EU.
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building in healthcare. Particular attention is given to 
marginalised groups, prisoners, human trafficking, including of 
street children and child soldiers, and to HIV/AIDS prevention 
and care. Demand reduction receives some attention in both 
the SCO strategy and the ASEAN plan, but plays a minor role 
compared with supply reduction and drug control. 
Nonetheless, the ASEAN plan focuses on a significant and 
sustainable reduction in drug use, envisaging intensification of 
awareness campaigns, aimed, in particular, at high-risk 
groups, and facilitating access to a range of treatment 
modalities. The SCO strategy focuses on the promotion of 
healthy lifestyle and looks at enhancing methods of treating 
drug addicts. The EU and OAS strategies take a broad-brush 
approach to demand reduction, utilising a range of 
components: prevention (increasingly targeted at reducing 
risks and at selected groups), treatment (towards 
rehabilitation including measures to reduce risks and harms or 
adverse consequences) and rehabilitation (linked to social 
reintegration and recovery).
Across all regions analysed, demand reduction activities fall 
into two main traditional areas of intervention: drug use 
prevention (to discourage or delay the use of drugs) and the 
treatment of addiction (to treat addiction and ensure 
rehabilitation and reintegration of drug users). Reducing the 
negative consequences of drug use is also addressed in some, 
but not all, documents.
Prevention
Preventing the use of drugs appears to be the cornerstone of 
all drug demand reduction interventions, although there are 
differences in the way in which prevention is viewed. Some 
documents focus on identifying at-risk groups and evidence-
based approaches while others rely on the belief that 
information alone can be effective in inducing behavioural 
changes. Some documents include both concepts.
According to the EU strategy and plan, for example, prevention 
is best achieved by system tailoring the delivery of prevention 
strategies according to the target group, prioritising some 
at-risk groups and risk factors and introducing the concept of 
quality standards. Along the same lines, the OAS promotes 
the implementation of measurable and evidence-based 
programmes, targeted at specific populations, and invites 
member states to disseminate information on the risks of 
drugs using mass media and the internet.
The SCO’s strategy is to use education and information 
campaigns, delivered by the mass media or during leisure 
activities, to prevent the use of drugs, especially by young 
people. Anti-drugs education should be included in 
extracurricular activities for young people. The ASEAN plan 
envisages that prevention interventions, including those 
negative effects on human rights, livelihoods and the 
environment. Against this background the OAS plan invites 
countries to consider integral, sustainable, alternative 
development and to reduce the supply of drugs, while 
expressly warning against the possible negative impact of 
these measures on the environment. Similarly, the new EU 
strategy acknowledges, for the first time in EU drugs policy 
documents, that the implementation of drug policy has the 
potential for unintended negative consequences.
I Demand reduction
Drug demand reduction is covered in all documents. There are 
important differences across regions, but three main 
approaches to demand reduction can be discerned: 
n  linked to social development, poverty reduction and health 
intervention in marginalised groups (AU and ECOWAS);
n  included in a security and drug control approach (SCO and 
ASEAN); or
n  integrated in a comprehensive, balanced approach (EU and 
OAS).
This classification, however, is not completely clear-cut. Some, 
more general, elements of all three approaches can be found 
— with different emphasis — in all strategies.
The approach to demand reduction taken by the two African 
organisations (AU and ECOWAS) is to improve capacity-
European Union drugs strategy 2012–20
Drug demand reduction consists of a range of equally 
important and mutually reinforcing measures, including 
prevention (environmental, universal, selective and 
indicated), early detection and intervention, risk and 
harm reduction, treatment, rehabilitation, social 
reintegration and recovery.
Organization of American States, Hemispheric drug 
strategy 2011–15
Demand reduction policies should include as essential 
elements universal, selective and indicated prevention, 
early intervention, treatment, rehabilitation and related 
recovery support services, with the goal of promoting the 
health and social well-being of individuals, families and 
communities, and reducing the adverse consequences 
of drug abuse.
Definition of drug demand reduction
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interventions, and increasingly they petition for high quality, 
standards and evidence.
The overall goals of drug treatment are very similar in the 
Americas and in Asia: recovery from addiction and the full 
reintegration into society of drug addicts. These are not 
dissimilar to the goals enunciated in the new EU strategy, 
which are described as recovery from drug use problems and 
dependency. The overall goal of the EU is to enhance the 
effectiveness of treatment by improving accessibility, 
availability and quality, putting the specific needs of drug 
users at the centre. Objective 6 under demand reduction of 
the OAS strategy has the same goal.
The ASEAN plan also focuses on a range of treatment 
modalities for different categories of drug users, with a view to 
scaling up coverage and accessibility. Similar attention to 
quality and to individual needs is expressed in the AU text, 
especially regarding the prevention and treatment of HIV/
AIDS. The ECOWAS plan envisages the creation of a network 
of treatment centres to implement best practice in treatment, 
including preventing HIV infection in vulnerable groups. 
Medical and rehabilitation measures are envisaged in the 
SCO’s strategy, which focuses on training for narcology 
specialists and research to enhance treatment methods.
Quality, evidence and measurability of results are central to 
the treatment approach envisaged in the demand reduction 
chapter of the OAS strategy. Probably one of the most crucial 
elements is the recognition that drug dependency is a chronic 
relapsing disease and, thus, it should be considered a public 
health issue. According to the OAS strategy, access to, and 
implementation of, treatment should be implemented through 
quality standards. The AU and the EU strategies envisage the 
development of quality standards in the treatment of problem 
drug use.
Risk and harm reduction
Reducing the risk of drug-related harm at both the individual 
and the society levels could be regarded as an implicit aim of 
all drug strategies. The 2009 UN political declaration 
establishes 2019 as a target date for states to reduce 
significantly and measurably drug-related health and social 
risks.
The term ‘harm reduction’, however, still generates some 
political controversy, and this is reflected in the way different 
strategies refer to this issue. In the EU, the term harm 
reduction was first included in the demand reduction chapter 
of the 2005–12 drugs strategy. In the new strategy (2013-20), 
the issue is formulated as follows: ‘the EU aims at reducing 
demand and supply of drugs as well as the health and social 
risks and harms caused by drugs’. From this wording, 
aimed at reducing spread of HIV/AIDS, should involve experts, 
media and civil society and should be targeted at high-risk 
groups.
The AU’s approach is interesting because it links drug use 
prevention (and treatment) to several qualitative concepts: 
comprehensive, accessible, evidence-informed, ethical and 
human rights based. It envisages setting minimum quality 
standards in the area of prevention throughout the continent.
Treatment
All drug strategies see treatment of drug use and addiction as 
a pillar of their demand reduction policies. Almost all 
strategies refer to a comprehensive range of treatment 
Commonly the concept of prevention is associated with 
the provision of information about the risks deriving from 
the use of drugs. The underlying idea is that people use 
information to make decisions about their behaviour. 
Nevertheless, the relation between information and 
making decisions about health-related behaviour is not 
straightforward, especially among young people. Many 
factors mediate the relation between information and 
behaviour. This could be one of the reasons why media 
campaigns aimed at preventing drug use do not always 
have the expected effects, and in some cases have 
clearly unwanted effects (Ferri et al., 2013). Research on 
prevention indicates that multifaceted approaches, 
including interactivity, and addressing social influence 
factors and building life skills, provide better results than 
those based only on the provision of information 
(EMCDDA, 2008). The need to improve the quality of 
prevention interventions along with the imperative of 
avoiding counterproductive effects led several 
international organisations to publish minimum quality 
standards. Among them are those produced by the 
UNODC (2013) and by the EMCDDA (2011). These 
organisations address different targets (the former, 
middle- and low-income countries; the latter, first and 
European countries) but in both cases standards are 
based on collaboration and use evidence-based 
methodology. The evidence-based approach takes 
account of the fact that new studies can necessitate 
modification of recommendations at any time, and for 
this reason the prevention strategy and other political 
documents need to remain flexible enough to 
accommodate latest findings. 
Is information the keyword of prevention?
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I International cooperation
Most of the objectives and actions in the area of international 
cooperation mentioned in the OAS, SCO and AU strategies 
and plans concentrate on internal drug policy within the 
region. Actions and objectives aim to promote and increase 
coordination and cooperation among the members of the 
regional organisation that ‘hosts’ the drug strategy or plan. In 
these cases, the drug strategy functions as an internal 
(regional) integration mechanism in drug policy. This is 
noticeable, for example, in the emphasis given in the OAS 
strategy to the need to strengthen joint or coordinated 
operations, taking into account the individual needs of each 
state, ratifying or adhering to international drugs treaties and 
harmonising national laws in the area of judicial cooperation 
and mutual legal assistance. Similarly, the SCO and the AU, 
aim to promote cooperation between source, transit and 
destination countries for drugs in their regions.
In contrast, the EU strategy, uniquely among the documents, 
deals with the issue of cooperation among member states in a 
specific chapter on coordination. Thus, the international 
cooperation chapter constitutes the external dimension of the 
EU drugs policy. The EU strategy also aims to increase 
collaboration with EU candidate countries and other 
neighbouring countries and to reinforce policy dialogues with 
partners such as the USA, Russia, Afghanistan, Pakistan, 
Central Asian Republic, China, Latin America and the 
Caribbean and Africa. At an international level, the EU aims to 
speak with a united voice to promote its approach to drugs 
and expand its political influence in the international arena 
through a balanced, human rights, health-oriented approach 
to the phenomenon.
I Other regional initiatives
Although it is not the role of this paper to look at regional 
initiatives other than drugs strategies and plans, it is important 
to mention the role played by the United Nations Office for 
Drugs and Crime (UNODC) in promoting worldwide a more 
strategic approach to drugs. The UNODC acts as catalyst for a 
number of programmes and plans involving multiple regions of 
the world. The EU has assumed a similar role in relation to 
candidate countries to the EU and neighbouring states.
especially the use of the term ‘as well as’, it is clear that risk 
and harm reduction is an overarching aim of the strategy as a 
component of the European demand reduction approach.
The OAS strategy refers to the concept using the expression 
‘reduction of the adverse consequences of drug abuse’ and 
includes it as one of the goals of its drug demand reduction 
chapter. In the remaining regions, harm reduction is not 
mentioned.
Prisons and alternatives
Prison is increasingly viewed in strategic documents as a key 
setting for the provision of health-related drug policy 
measures. The AU action plan calls for evidence-based 
interventions to be delivered in prisons and invites Member 
States to reduce overcrowding and improve prison conditions. 
The plan recognises that inadequate prison conditions may be 
conducive to drug use and the spread of HIV infection. The 
OAS plan proposes the adoption of drug treatment services in 
prison in accordance with scientific protocol and quality 
standards. However, it offers some leeway to those countries 
where such a policy would conflict with national laws, by using 
the expression ‘as far as possible’. In the EU, emphasis is put 
on equality of services available outside prison and after 
release from prison. Member States are asked to increase the 
availability and coverage of drug demand reduction measures 
in prison settings. There is a reminder of the right to healthcare 
and human dignity enshrined in the European Convention on 
Human Rights and the EU Charter of Fundamental Rights. The 
ECOWAS drug plan invites countries to provide access to 
treatment for drug-dependent persons, including those in 
prison, but there is no mention of prison policies in the drugs 
strategy or plan of ASEAN or the SCO where measures are 
enacted at national level only.
It is increasingly common for strategic documents to consider 
alternatives to punishment or incarceration. Both the OAS and 
the AU promote alternatives to criminal prosecution or 
imprisonment such as treatment, rehabilitation, social 
reintegration and recovery of drug offenders and young 
offenders and, in Africa, of street children and child soldiers. 
The EU 2013–16 action plan raises the bar even further by 
calling on Member States to implement alternatives to 
coercive sanctions.
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Other regional initiatives exist and are worth mentioning 
because they contribute to bringing together the policies of 
countries belonging to the same regions. These include the 
Colombo plan, the Arab Interior Minister Council, the League 
of Arab States and, in particular, at European level, the 
Pompidou Group of the Council of Europe.
The Pompidou Group is an intergovernmental organisation 
formed in 1971 to contribute to the development of 
multidisciplinary, innovative, effective and evidence-based 
drug policies in its Member States. The Pompidou Group is 
made up of 36 Member States, but its technical cooperation 
also involves other European states which are not members of 
the Pompidou Group, such as Albania, Ukraine and states 
from the Mediterranean Basin such as Algeria, Tunisia and 
Lebanon.
n  Sub-regional action plan on drug control between 
UNODC and Cambodia, China, Lao, Myanmar, 
Thailand and Vietnam 2011–13
n  UNODC regional programme for West Africa 2010–
14.
n  UNODC regional programme on drug control, crime 
prevention and criminal justice reform in the Arab 
States 2011–15
n  Comprehensive action plan on drugs between the 
European Union, Latin America and the Caribbean, 
1999
n  Action plan on drugs between the EU and the 
Western Balkan countries 2009–13, integrating the 
2013 political declaration
n  Action plan on drugs between the EU and Central 
Asian states 2014–20
n  Strategy on substance abuse and public health, Pan 
American Health Organization, World Health 
Organization, 2010
n  Plan of action on psychoactive substance use and 
public health, Pan American Health Organization, 
World Health Organization, 2011
Strategies and action plans endorsed by 
international organisations
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I African Union
The African Union (AU) was established in 2000, on the basis of the dissolved 
Organisation of African Unity. Its main vision is an integrated, prosperous and peaceful 
Africa. The AU is headed by the Assembly of heads of state and government. The 
Executive Council, composed of ministers or authorities designated by Member 
States, takes decisions on policies in areas of common interest. The Commission is the 
Secretariat of the Union entrusted with executive functions. The Parliament exercises 
advisory and consultative powers.
Continent Africa
Intergovernmental organisation African Union (AU)
Member States (current) Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African 
Republic, Chad, Comoros, Congo, Democratic Republic of Congo, Ivory Coast, Djibouti, Egypt, 
Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea Bissau, Equatorial Guinea, Kenya, Lesotho, 
Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, 
Rwanda, Sahrawi Arab Democratic Republic, Sao Tome and Principe, Senegal, Seychelles, Sierra 
Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, 
Zambia, Zimbabwe
Drug strategies/plans Plan of action on control of illicit drug trafficking and abuse in Africa (2002–06)
Revised AU plan of action on drug control and crime prevention (2007–12)
AU plan of action on drug control (2013–17)
The regional profiles address synthetically the organisational 
structure, the drug strategy/plan and the drug coordination 
arrangements of the six intergovernmental organisations 
considered in this paper.
Part II
Regional strategies
The new AU plan of action on drug control (2013–17), adopted 
by the heads of states in January 2013, represents a 
substantial change to African drug policy. It aims to improve the 
health, security and socioeconomic well-being of people in 
Africa by reducing drug use, illicit trafficking and associated 
crimes. This plan places special emphasis on combating the 
drugs phenomenon through a systematic approach to drug-
related healthcare. It places particular emphasis on the 
health-related aspect of drug policy by incorporating drug use 
prevention and drug treatment into public health programmes. 
Respect for human rights and a distinction between drug use 
and other forms of more serious crime are another two 
important characteristics of this approach. According to the 
plan, the first two years will see the implementation of minimum 
quality standards for the treatment of drug dependence, a 
regional assets recovery policy and a strengthening of research, 
monitoring and evaluation. Overall, it is expected that this plan 
will contribute to a decrease in illicit trafficking and supply 
trends and to a wider access to licit drugs for medical use. It 
calls for drug-related services to be based on the best available 
evidence and focuses on an increased reporting and evaluation 
capacity with more robust data collection systems.
The new plan also reinforces regional coordination in the field 
of drugs. At the top of the institutional framework on drugs is 
the AU Conference of Ministers of Drug Control. The Ministers 
meet biennially to review the progress of implementation and 
recommend appropriate action to the Heads of State Summit.
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In 2008, ECOWAS, in collaboration with the UNODC, drafted 
the Praia plan of action 2008–11 and a political declaration 
against illicit drug trafficking. The action plan and the 
declaration were later endorsed by ECOWAS heads of state. 
The plan was the first of its kind in the region and engages the 
ECOWAS institutions and member states around five main key 
policy areas: mobilisation of political leadership; increased law 
enforcement cooperation; criminal justice; drug use and 
related health problems; and reliable monitoring systems. For 
each of the problems identified, the plan selects an objective, 
the strategy most suited to achieve it, the activities required 
and the party responsible for execution at national and 
regional level. In 2013, at the 42nd ordinary session of the 
authority of Heads of State and Government, it was decided to 
extend the period of the plan by two years, in order to sustain 
the fight against drug trafficking and consolidate the financial 
support base for its effective implementation.
The ECOWAS regional action plan has inspired the 
development of subregional initiatives, such as The Dakar 
Initiative, a subregional Ministerial Conference on Drugs held 
in 2011 in Dakar. This initiative was attended by six 
subregional countries, namely Guinea-Bissau, Guinea, the 
Gambia, Mali, Cape Verde and Senegal. It was sponsored by 
Spain through its interior ministry, UNODC and ECOWAS. The 
I  Economic Community of West African States (ECOWAS)
The Economic Community of West African States (ECOWAS) was established in 1975 
with the aim of promoting cooperation and integration with a view to establishing a 
West African economic union. Since then, social and cultural matters have gradually 
been added. The institutional framework includes a Council of Ministers entrusted with 
the legislative power, a Commission (previously Secretariat), which represents the 
executive power, and the conference of Heads of State and Government as the main 
policy-making body. The Community Parliament has an advisory role. The ECOWAS 
includes the Community Court of Justice, which examines member adherence to 
obligations set forth under ECOWAS law as well as making declarations on the legality 
of ECOWAS decisions and mandates, and the Bank for Investment and Development 
(EBID), the financial arm of ECOWAS and responsible for private sector promotion and 
financing in West Africa.
Continent Africa
Intergovernmental organisation Economic Community of West African States (ECOWAS)
Member States (current) Benin, Burkina Faso, Cap Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea Bissau, Liberia, Mali, 
Niger, Nigeria, Senegal, Sierra Leone, Togo
Drugs strategies/plans Political declaration on the prevention of drug abuse, illicit drug trafficking and organised crime in 
West Africa (Abuja Declaration, 2008)
Regional action plan to address the growing problem of illicit drug trafficking, organised crime and 
drug abuse 2008–11
Regional action plan has also given impetus to national, 
bilateral and subregional initiatives, for example the West 
African Coast Initiative (WACI), implemented by UNODC, the 
United Nations Office for West Africa (UNOWA) and Interpol, 
and the UN Department of Peacekeeping Operations (DPKO) 
programme in five countries: Ivory Coast, Liberia, Sierra 
Leone, Guinea Bissau and Guinea.
In the area of coordination, the ECOWAS Commission is the 
main responsible for overall coordination and monitoring of 
regional initiatives in the field of drugs. A Commission 
Operation Plan was adopted in 2009 to follow the 
implementation of the regional action plan.
In 2013, a new West Africa Commission on Drugs was set by 
the Kofi Annan foundation. Composed by 12 African 
personalities, from the worlds of politics, civil society, health, 
security and the judiciary, the new Commission intends to 
analyse the problems of drug trafficking and use in order to 
deliver an authoritative report and comprehensive policy 
recommendations by the end of 2013. The Commission will 
follow three basic objectives: mobilising public awareness and 
political commitment, developing evidence-based policy 
recommendations and developing local and regional 
capacities and ownership (11).
(11)  West Africa Commission on Drugs (http://www.wacommissionondrugs.org/).
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Among the intergovernmental organisations considered in this 
study, the OAS was the first to adopt a drug strategy — which 
it called as program of action — in 1986. Subsequently,  
another two programmes of actions were adopted in 1990 and 
the Anti-drug strategy in the hemisphere was introduced in 
1996. In 2010, the OAS General Assembly approved a new 
hemispheric drug strategy, updating the 1997 Anti-drug 
strategy. The new strategy calls for a rebalance towards a 
comprehensive and health-oriented approach. It aims at 
helping countries to develop policies focusing not only on 
supply and control but also on drug dependence, which is 
defined as a chronic relapsing disease. Presenting the 
document, the OAS General Secretary underlined that the 
change of name, from an ‘Anti-drug strategy’ (1997), to an 
‘Hemispheric drug strategy’ (2010), signifies a change of vision 
in drug policy in the region as not being against something but 
(12)  On June 3, 2009, the Ministers of Foreign Affairs of the Americas adopted 
resolution AG/RES. 2438 (XXXIX-O/09), that resolves that the 1962 
resolution, which excluded the Government of Cuba from its participation in 
the inter-American system, ceases to have effect in the Organization of 
American States (OAS). The 2009 resolution states that the participation of 
the Republic of Cuba in the OAS will be the result of a process of dialogue 
initiated at the request of the Government of Cuba, and in accordance with 
the practices, purposes, and principles of the OAS. (www.oas.org)
I Organization of American States (OAS)
The Organization of American States (OAS) was established in 1948 among the 
countries of the American continent with the objective of achieving an order of peace 
and justice, to promote their solidarity, to strengthen their collaboration, and to defend 
their sovereignty, their territorial integrity and their independence. Today, the OAS 
brings together all 35 countries of the Americas and has granted observer status to 67 
states, as well as to the EU. The General Assembly is the supreme organ of the OAS 
and comprises the delegations of all the member states. The Permanent Council deals 
with matters entrusted to it by the General Assembly as well as the Meeting of 
Consultation of Ministers of Foreign Affairs; it also monitors the maintenance of 
friendly relations among the member states and the observance of the standards 
governing General Secretariat operations.
Continent America
Intergovernmental organisation Organization of American States (OAS)
Member states (current) Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, 
Cuba(12), Dominica (Commonwealth of), Dominican Republic, Ecuador, El Salvador, Grenada, 
Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts 
and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, The Bahamas (Commonwealth 
of), Trinidad and Tobago, United States of America, Uruguay, Venezuela (Bolivarian Republic of)
Drugs strategies/plans Inter-American program of action of Rio de Janeiro against the illicit use and production of narcotic 
drugs and psychotropic substances and traffic therein, 1986
Inter-American program of Quito: comprehensive education to prevent drug abuse, 1990
Declaration and program of action of Ixtapa: guidelines for implementing the program of Rio 
inter-American program of Quito, 1990
Anti-drug strategy in the hemisphere, 1997
Action plan for the implementation of the anti-drug strategy in the hemisphere, 1998
Hemispheric drug strategy 2011–15
Plan of action 2011–15
in favour of the well-being of its people (13). The new document 
covers five fields (key areas): institutional strengthening, 
demand reduction, supply reduction, control measures and 
international cooperation. In May 2011, a plan of action 
(2011–15) was adopted to implement the strategy’s objectives.
To strengthen coordination in the field of drugs in the region, 
the OAS General Assembly established, in 1986, the Inter-
American Drug Abuse Control Commission (CICAD), to 
promote regional coordination and cooperation among OAS 
Member States; to reduce the production, trafficking and use 
of illegal drugs; and to address the health, social and criminal 
consequences of the drug trade. CICAD is responsible for 
following up on the implementation of this plan while the 
Executive Secretariat is responsible for executing 
programmes and actions in support of this strategy as 
requested by the Commission. The multilateral evaluation 
mechanism (MEM) (14) will be used to monitor, evaluate and 
(13)  New Hemispheric Drug Strategy, at http://www.cicad.oas.org/en/
basicdocuments/Hemispheric%20Drug%20Strategy100603.pdf
(14)  The multilateral evaluation mechanism (MEM) was created in 1998 to 
strengthen mutual confidence, dialogue and hemispheric cooperation in 
order to deal with the drug problem with greater efficacy. It highlights both 
results achieved as well as obstacles faced by member countries in tackling 
the drugs problem.
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of the plan will be undertaken in 2015. ASOD has five working 
groups to carry out the recommended action lines prescribed 
in the ASOD work plan. They are law enforcement, alternative 
development, research, treatment and rehabilitation and 
preventative education.
Cooperation in the field of drugs among ASEAN countries 
dates back to the first ASEAN declaration of principles to 
combat the abuse of narcotic drugs in 1976. Since then, 
ASOD has been the main coordination body. ASOD meets 
annually and is mandated by the plan to review 
implementation annually and to carry out a mid-term review in 
2012 and a final assessment in 2015.
In 2009, an expert group, ASEAN Senior Officials on Drugs 
Matters (ASOD), adopted the ASEAN work plan on combating 
illicit drug production trafficking and use 2009–15, which 
reiterates the commitment, first made in 1998 by ASEAN 
governments, to achieve a drug-free region by 2020 and sets 
this as a specific objective. The ASEAN ministers 
subsequently brought this date forward to 2015 to 
demonstrate the scale of member states’ concerns about the 
threat posed by drug markets to the security and stability of 
the region (15). The ASEAN plan commits countries of the 
region to work towards three objectives: a significant and 
sustainable reduction in illicit crop cultivation; a reduction in 
the illicit manufacturing and trafficking of drugs; and a 
reduction in the prevalence of illicit drugs. A final assessment 
(15)  2000 Bangkok political declaration in pursuit of a drug-free ASEAN 2015 at 
http://cil.nus.edu.sg/rp/pdf/2000%20Bangkok%20Political%20
Declaration%20in%20Pursuit%20of%20a%20Drug-Free%20ASEAN%20
2015-pdf.pdf
I Association of Southeast Asian Nations (ASEAN)
The Association of Southeast Asian Nations (ASEAN) was established in 1967 to 
maintain and enhance peace in the region by promoting political security and 
economic and socio-cultural cooperation. ASEAN comprises 10 countries: Brunei 
Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, 
Singapore, Thailand and Vietnam. ASEAN also has 10 so-called ‘dialogue partners’: 
Australia, Canada, China, the EU, India, Japan, New Zealand, the Republic of Korea, 
Russia and the USA. The United Nations Development Program (UNDP) also has 
dialogue status. The ASEAN summit comprises the heads of state and government of 
the ASEAN member states. The foreign ministers of the ASEAN members meet in the 
Coordinating Council while the ASEAN Community Councils deal with economic and 
socio-cultural matters and issues of political security. A Secretary General and a 
Secretariat ensure the coordination of ASEAN organs and implementation of ASEAN 
projects and activities. 
Continent Asia
Intergovernmental organisation Association of Southeast Asian Nations (ASEAN)
Member states (current) Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, 
Thailand, Vietnam
Year or creation 1967
Drugs strategies/plans ASEAN regional policy and strategy in the prevention and control of drug abuse and illicit 1984
ASEAN work plan on combating illicit drug production trafficking and use 2009–15
improve national and hemispheric policies and actions to 
address the world drug problem. Members are called on to 
actively participate in this mechanism as part of an ongoing 
political process. CICAD’s mandate includes, but is not limited 
to, the execution of regional programmes, the promotion of 
drug related-research, developing and recommending 
minimum standards and carrying out regular multilateral 
evaluations. In 2000, CICAD established the Inter-American 
Observatory on Drugs (OID), which helps countries to improve 
the collection and analysis of drug-related data, promotes the 
establishment of national drug observatories and the use of 
standardised data systems and methodologies, and provides 
scientific and technical training for, and the exchange of 
experiences among, professionals working on the drugs 
problem. 
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The SCO is structured as an intergovernmental network and 
decisions are taken at annual summits and regular meetings 
of the heads of government, foreign ministers and other 
high-level officials of its member states (Bailes et al., 2007, 5, 
in Hoffman 2011). As far as drug coordination is concerned, 
the implementation of the plan is reviewed once a year at the 
meeting of senior officials of competent bodies of the SCO 
member states. The Heads of State Council (HSC) is the 
highest decision-making body in the SCO. It meets once every 
year to take decisions and give instructions on all important 
issues of SCO activity. There are also regular meetings at the 
level of speakers of parliament, secretaries of security 
councils and ministers. The organisation has two permanent 
bodies — the Secretariat and the Regional Counter-Terrorism 
Structure.
I The Shanghai Cooperation Organisation (SCO)
The Shanghai Cooperation Organisation is an intergovernmental security 
organisation founded in 2001 in Shanghai by China, Kazakhstan, 
Kyrgyzstan, Russia, Tajikistan and Uzbekistan. Its structure is based on 
that of a military organisation, the Shanghai Five, founded in 1996 by the 
same countries (excluding Uzbekistan). The SCO widens the scope of 
collaboration among its members, which now covers trade and the 
economy, culture and education, and security and drugs. Its main goal is 
to work jointly to maintain and ensure peace, security and stability in the 
region, moving towards the establishment of a new, democratic, just and 
rational political and economic international order. Its six full members 
account for a quarter of the world’s population. 
Continent Asia
Intergovernmental organisation Shanghai Cooperation Organisation (SCO)
Member states (current) Kazakhstan, China, Kyrgyzstan, Russia, Tajikistan, Uzbekistan
Drugs strategies/plans Counter narcotic strategy of the Shanghai Cooperation Organisation member states 2011–16
The Counter narcotic strategy of the Shanghai Cooperation 
Organisation 2011–16 was adopted by the Heads of State 
Council in June 2011. Its main objective is to drastically 
reduce illicit drug trafficking, precursors and the use of drugs 
by 2017. The strategy focuses on an increase in efficient law 
enforcement to counteract the illicit trafficking and production 
of drugs. The idea of a security belt to address drug trafficking 
from Afghanistan is key to the strategy. The strategy also 
addresses the demand reduction aspect of drug control, 
promoting drug use prevention through mass media 
campaigns and improvement of medical and rehabilitation 
care. At the 4th meeting of the heads of counternarcotic 
agencies of the SCO member states in 2013, the countries 
approved the Plan of action for 2013–14. The plan aims to 
implement the programme of measures envisaged to fulfil the 
Counter narcotic strategy.
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process is also enhanced, with explicit support given to the 
involvement of young people, drug users and clients of 
drug-related services in policy development. The strategy 
outlines a model for EU drugs policy that is integrated, 
combining all aspects of drugs activities; balanced, 
concentrating equally on demand and supply reduction 
measures; and evidence-based, drawing on scientific findings. 
Two consecutive four-year action plans will translate the 
strategic priorities into specific actions with a timetable, 
responsible parties, indicators and assessment tools. The first 
of these action plans, for 2013–16, was adopted on 6 June 
2013. It is structured around two policy areas: drug demand 
reduction and drug supply reduction; and three cross-cutting 
themes: coordination; international cooperation; and 
information, research, monitoring and evaluation. The 
European Commission will assess the implementation of this 
action plan every two years and will organise a final external 
evaluation in 2016.
Over the years, the steering of European drug policy has been 
carried out, within the framework of the EU Council of 
Ministers, by a group of experts — the Horizontal Drugs Group 
I European Union (EU)
The European Union was established in 1957 as the European Economic Community 
(EEC). The main purpose at the time was the economic integration among its 
members. Over the years, the membership of the EU has evolved, as well as its 
mandate. As an organisation it now spans all policy areas, from development aid to the 
environment. The change of name from the EEC to the EU in 1993 reflected this 
evolution. One of the EU’s main goals is to promote human rights both internally and 
around the world. The core values of the EU are human dignity, freedom, democracy, 
equality, the rule of law and respect for human rights. The EU is composed of three 
main institutions: the Council of the Ministers, made up of the representatives of 
Member States and holding the legislative power; the European Commission, an 
independent organ which holds the executive power and the power of legislative 
initiative; and the European Parliament, composed of elected members and which 
holds control and legislative powers with the Council. 
Continent Europe
Intergovernmental organisation European Union (EU)
Member states Austria, Belgium, Bulgaria, Cyprus, Croatia, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom 
Year or creation 1957
Drugs strategies/plans European plan to combat drugs 1990
European plan to combat drugs 1992
Action plan to combat drugs 1995–99
EU drugs strategy 2000–04
EU action plan on drugs 2000–04
EU drugs strategy 2005–12
EU drugs action plan 2005–08
EU drugs action plan for 2009–12
EU drugs strategy 2013–20
EU drugs action plan for 2013–16
The first European plan on drugs dates back to 1990. Since 
then, several drug strategies and action plans have been 
endorsed by its Member States, which now number 28. 
Although these documents do not impose legal obligations on 
EU Member States, they promote a shared model with defined 
priorities, objectives, actions and metrics for measuring 
performance.
A new EU drugs strategy (2013–20), endorsed by the Justice 
and Home Affairs Council of the EU, constitutes the ninth 
strategic document on illicit drugs endorsed by EU Member 
States since 1990. The new strategy sets objectives geared 
towards the disruption of illicit drug trafficking through 
intelligence-led law enforcement and a more effective use of 
the criminal justice system. It also proposes that special 
attention be paid to communication technologies, which play 
a significant role in the spread of drugs, particularly new 
psychoactive substances. For the first time, the 2013–20 
strategy incorporates as a policy objective a reduction in the 
health and social risks and harms caused by drugs, alongside 
the two traditional drug policy aims of reducing supply and 
demand. The role of civil society in the drug policy-making 
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Regional drugs strategies as part of a wider integration 
process
Regional action plans and drug strategies did not arise 
spontaneously from the will of countries of a same region 
sharing similar social or security problems. Instead they were 
born of a wider process of integration, often of an economic 
nature, undertaken by a group of neighbouring countries 
within the boundaries of an intergovernmental organisation 
after a wide range of policy reforms in the areas of trade, 
environment, immigration or culture.
It is not by chance that the first European action plan on drugs 
appeared 30 years after the creation of the EEC, and that the 
first Anti-drug strategy in the OAS was adopted almost 40 
years after that organisation’s creation. The same can be said 
for the ECOWAS, the AU, ASEAN and the SCO (16). Regional 
drug policy can therefore be considered as one of those policy 
areas which are developed at a certain point in the life of an 
intergovernmental organisation and need to be understood 
within the level of integration among its members.
Regional strategies as tools for common views on drugs
An interesting feature inherent to the process of drafting a 
regional drugs strategy or drugs plan is the commitment to a 
unified regional vision on drugs among countries which often 
have not only different views but also different legislations and 
policies.
It seems that the mere act of engaging in the drafting 
negotiations for a new regional drugs plan or strategy creates 
the conditions for participating countries to share objectives, 
agree on definitions and commit to joint activities. Inevitably, 
this leads to a process of confrontation of beliefs, concepts, 
effective practice and ideological stance, in which positions, 
at first divergent, must eventually be combined into common 
concepts and views.
This developmental process is particularly visible in those 
strategies and plans that have been regularly renewed. 
Indeed, the debates and the preparatory work generated 
around the draft of a new document can create opportunities 
for new ideas, new trends and new approaches to find their 
place.
(16)  The European Economic Community changed its name to the European 
Union in 1993, The African Union was established in 2000 on the basis of the 
dissolved Organisation of African Unity. The Shanghai Cooperation 
Organisation was founded in 2001 on the basis of the Shanghai Five, which 
was founded in 1996. 
— representing the countries, the European institutions and 
the agencies involved. The monthly meetings have served as a 
drafting committee, review board and assessment group for 
EU legislation, policy position and strategies and plans. In 
addition, since 2005 a biannual meeting of the national drugs 
coordinators has provided a forum for informal dialogue at a 
high political level. The European Commission, using its power 
of initiative, has often steered European drug policy towards 
the Union’s principles and values, with the EMCDDA and other 
agencies, such as Europol, playing an active role in informing 
and contributing to the decision-making process with specific 
data and analyses.
I Findings
The analysis of regional drug strategies is interesting because, 
from an international drug policy perspective, these 
documents introduce a third political dimension, located 
between national plans, which aim to address purely national 
or local issues, and policy declarations at the UN level, which 
represent a very large consensus, often on a wide scale. This 
paper, comparing regional approaches, highlights specificities 
that do not emerge in the UN context and which are too varied 
to be analysed at national level.
It is too soon to say if and how these regional initiatives will 
influence drug control internationally, and that, in any case, is 
not the purpose of this paper, but undoubtedly they represent 
an interesting policy development within the international 
drugs policy scene, and well worth a look.
Overall support to international drug control principles
This paper reveals the existence of official overall support, in 
all regions analysed, for the main international foundations of 
drug policy, in other words the three main UN Conventions and 
the successive UN political declarations and action plans. The 
reduction of demand and of supply of drugs are objectives 
addressed by all drugs strategies and plans. The language in 
these texts is overall in line with the UN commitment, 
enshrined by the 1998 UN plan and restated in the political 
declaration of 2009, of eliminating or significantly reducing 
the phenomenon. In some strategies the emphasis is more 
towards the elimination of the phenomenon; in others, the 
expressed aim is more towards its measurable reduction. In 
both cases, there is coherence between UN guidance and 
regional strategies.
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the change in the title of the strategy from Anti-drug strategy 
(1997) to the new Hemispheric drug strategy (2011) 
represents, in the words of the OAS General Secretary, a 
renewed emphasis on the health and social components of 
the strategy. In the EU, where the principle of a balanced 
approach has been followed since the first plans in the 
mid-1990s, the new drugs strategy (2013–20) includes a 
reduction in drug-related health and social risks and harms 
among its main policy objectives, related, conceptually, to the 
main policy objectives of reducing drug demand and supply.
At the same time, this development must not be read as taking 
attention away from drug control, which remains a priority, 
and, in fact, control of drugs is increasingly seen as part of a 
broader security agenda in several regions.
Monitoring and understanding for better decisions
Another relevant trend worth mentioning is the increased 
attention given to the understanding the drug phenomenon 
and to the measurability of the responses to tackle it. In 
almost all strategies analysed, the importance of monitoring 
systems to collect data, analyse trends and support decision-
making towards evidence-based policies is emphasised.
Very prominent are references to quality standards, the need 
to share best practice and the development of indicators to 
assess the performance of demand reduction, and 
increasingly supply reduction, interventions. This approach is 
key in the EU, where the new strategy promotes a balanced, 
integrated, but above all, evidence-based approach, but also in 
the OAS’s Hemispheric strategy and in the AU’s strategy, 
which promotes the establishment of national observatories, 
the adoption of scientific quality standards and the 
implementation of more evidence-based policies.
Evaluation of strategies and action plans
As far as the assessment of the implementation of these texts 
is concerned, all propose some sort of assessment 
mechanism such as annual reports or — in a few cases — 
mid-term or final evaluations. It is less clear, however, what 
form these assessments will take. A few documents identify 
the authorities in charge of assessing progress by means of 
annual or biennial reports. But the scope and the objective of 
these assessments are rarely explicitly mentioned, for 
instance whether the assessment will look at the impact of the 
action or at its execution. Some documents offer more scope 
than others for the assessment of their implementation 
because of the way in which they are drafted. For instance, the 
AU and EU action plans explicitly envisage the objectives and 
actions and also performance indicators, dates for 
achievements and in some cases actors and expected 
Regional drug strategies: legally or politically binding?
The issue of the accountability of these documents and the 
‘obligations’ they put on members of a regional organisation is 
not easy to assess. It is clear that governments that endorse 
these documents are politically bound to them. However, 
countries maintain a large degree of national autonomy in the 
field of drugs. Indeed, legally speaking, these documents are 
not binding, and the lack of binding power has been at times 
criticised as providing leeway for countries to agree on 
something and disregard expectations once a new 
government with another perspective comes to power. While 
this possibility cannot be completely avoided, it seems that 
regional drug strategies and plans — even non-binding ones 
— do have a value. Over time they may fulfil a normative 
function and, in the short term, they facilitate policy dialogue 
and support consensus-building among the members of the 
inter-governmental organisation and between member states 
and third countries.
Rebalancing towards a qualitative health-orientated drug 
policy
The words of the Commissioner for Social Affairs of the AU, 
presenting the new AU plan of action on drug control, 
succinctly describes the increased attention to health and 
social aspects in drug policy: ‘While drug control in Africa has 
tended to focus more attention on supply reduction this Plan 
proposes to restore the balance and pay greater attention to 
health and other social consequences of drug use, while not 
neglecting law enforcement approaches’ (17).
In addition, in Africa, the fourth plan of the AU (2013–17) 
focuses on expanding evidence-based services to improve 
health and social conditions, stressing the need to counter 
drug trafficking and related challenges in accordance with 
human rights principles. Other important issues are the 
increased attention to food security and poverty reduction 
linked to alternative development, which is infused by social 
and development issues in the AU strategy. This new health-
orientated approach is not exclusive to AU drug policy but is 
an important feature that cuts across several strategies. The 
recent drug strategies adopted in the Americas (2011) and in 
Europe (2013) share this feature, which seems to reflect (at 
least in part) a steady process that, strategy after strategy, is 
increasing the role of health and social policies in the field of 
drugs.
The hemispheric drug strategy of the OAS makes extensive 
use of demand reduction concepts and promotes measures to 
reduce the negative consequences of drug use. In particular, 
(17)  Foreword of the AU plan of action on drug control, CAMDC/exp/2(V), 
submitted for consideration by the 5th session of the Africa Union 
Conference of Ministers of drug control (CAMDC5).
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Preventing drug use is the key area shared by all texts, but the 
measures described to achieve this goal are diverse, ranging 
from mass media campaigns to interventions tailor-made to 
address specific risk factors or populations. In the area of 
treatment, the majority of texts analysed call for evidence-
based practice. The goal of drug treatment is always the same, 
i.e. to treat addiction and promote social reintegration. The 
recovery from addiction and the full reintegration and 
resocialisation of drug addicts into society is the objective 
most often mentioned. Moreover, some strategies focus their 
attention on improving the effectiveness of treatments 
through better access to treatment, wider coverage and better 
quality of services provided. The policy of reducing harm (and 
risk) caused by drugs is specifically addressed only in the EU 
strategy. It is referred to in the OAS strategy, albeit with 
different wording — a reduction of the adverse consequences 
of drug abuse — and is not mentioned in the other strategies 
and plans analysed.
Supply reduction approaches adopt a common paradigm of 
doing ‘more and better’. More collaboration among national 
law enforcement services, more intelligence-led activities and 
more exchange of data and intelligence are among the 
measures most often mentioned. The quest for more 
effectiveness, meaning better results, in reducing, or in some 
cases eliminating, the illicit supply of drugs is evident across 
plans and strategies. The intention to monitor law enforcement 
and supply reduction activities and their results, as mentioned 
in a few texts, appears to be an interesting innovation.
Finally it can be argued that policy plans and strategies are 
nothing more than words on paper. It is their implementation 
into concrete actions on the ground that matters. However, 
these plans and strategies hold in themselves an important 
symbolism. They represent the commitment of a group of 
governments to go in a certain direction in the field of drugs, 
choosing rhetoric and language, objectives and actions. This 
paper brings to the attention of professionals and decision-
makers the many similarities and the important differences 
existing among these documents.
outputs. The ECOWAS and the AU drugs plans include an 
implementation matrix as an annex.
In general, however, it appears that the evaluation of these 
plans is left rather vague. For example, a common feature of 
all the action plans is a failure to identify the resources that 
will be allocated to their implementation and warning 
mechanisms if objectives are not achieved. In addition, in 
most cases the actors and schedule of implementation are 
not specified and nor is the scope of the expected outcomes.
Concluding remarks
In terms of content, the background to the analysed texts is 
the same, coherently reflecting the UN conventions, 
declarations and plans. However, heterogeneity of approach is 
more apparent in the field of demand reduction than in the 
area of supply reduction, where the approach is relatively 
more uniform.
The OAS strategy is the only one to explicitly define and 
recognise drug dependence as a chronic relapsing 
disease. The strategy calls on member states to integrate 
drug treatment into national public health systems. The 
ASEAN and SCO texts are the only ones to envisage a 
quantitative target (a drug-free region and a drastic 
reduction of the phenomenon, respectively) and a date 
(2015 and 2017, respectively) for the achievement of the 
main goal of their strategies. The AU plan is the only one 
that recognises that in the past drug control has tended 
to focus more on supply reduction and now aims at 
restoring the balance with demand reduction. The 
ECOWAS plan is the only one to include an annex giving 
the estimated budget for each action. The EU is the only 
region that expressly addresses harm (and risk) 
reduction as a policy objective and that will entrust an 
external party to assess the implementation of its 
eight-year strategy in 2020.
Some unique specificities
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